{"id":"W2024010256","doi":"10.1517/14712598.2013.770835","title":"Vedolizumab for Crohn's disease","year":2013,"lang":"en","type":"review","venue":"Expert Opinion on Biological Therapy","topic":"Inflammatory Bowel Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":12,"is_retracted":false,"has_abstract":true,"ca_institutions":"Western University; Robarts Clinical Trials","funders":"","keywords":"Vedolizumab; Medicine; Crohn's disease; Expert opinion; Adverse effect; Disease; Ustekinumab; Inflammatory bowel disease; Prednisone; Monoclonal antibody; Placebo; Intensive care medicine; Immunology; Internal medicine; Infliximab; Antibody; Alternative medicine; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0001492208,0.000667508,0.0007969751,0.00006628218,0.0001454189,0.00005654387,0.000589722,0.0007225404,0.0002755618],"category_scores_gemma":[0.0001706179,0.0004210191,0.001088768,0.00006102655,0.000152712,0.000003314936,0.0001044777,0.0001685683,0.0002127012],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00004251158,"about_ca_system_score_gemma":0.0002025879,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":9.745715e-7,"about_ca_topic_score_gemma":7.009558e-8,"domain_scores_codex":[0.9976246,0.0003338774,0.0004801636,0.0009507733,0.0001416604,0.0004689434],"domain_scores_gemma":[0.9984286,0.00007769822,0.0002383182,0.000815853,0.00008385465,0.0003556868],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0007350578,0.0002164147,0.000002978513,0.000155891,0.0001414868,0.00001938405,0.000004557788,4.57064e-7,0.00004956167,0.000493662,0.02388582,0.9742947],"study_design_scores_gemma":[0.0006541154,0.0004297517,0.0001836648,0.0005095046,0.000001873283,0.000002855221,0.000003042401,0.000001698397,0.00001724589,0.0001120061,0.9974766,0.0006076266],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0001160833,0.9955894,0.0001147179,0.00005568814,0.0009889804,0.002640535,0.0002335173,0.00006120229,0.0001998762],"genre_scores_gemma":[0.00002624016,0.9898182,0.0002195659,0.001108245,0.002396537,0.003406162,0.002774145,0.00009042865,0.000160502],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9736871,"threshold_uncertainty_score":0.9998242,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.124737181594895,"score_gpt":0.3899971346007448,"score_spread":0.2652599530058498,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}